u/bpc_sceptic

The order I actually check things in, for anyone building a process rather than asking about one supplier.

First, the record: source page, verification log, and how many separate lots have been tested rather than how many tests exist. Second, the paperwork: ask for a batch-specific certificate and see what comes back and how fast. Third, the logistics: quoted lead time, minimum quantity, which lines are held in regional stock. Fourth, buy small and test it yourself.

Nothing in that list is exotic and all of it is answerable before you spend real money. Most of the disappointment posts on this board skipped step two.

The engineering problem was duration: native amylin is short-acting and aggregation-prone. A long-acting analogue suitable for weekly administration is what makes the combination clinically interesting.

what does the certificate actually carry — that is the whole question

rui_only_ro is right that a pure something-else is still something else.

Agreed — and the preclinical to clinical gap is where nearly all the overclaiming happens.

Right, and a point or two between services is ordinary. It is agreement, and every month somebody posts it as a scandal.

regulatory status varies by jurisdiction and it has moved recently

Careful — that is a dosing intuition carried over from another board and there is no basis for it here.

A certificate with a purity figure and no method line is not falsifiable. You cannot reproduce it, you cannot check it, and it tells you nothing about how the number was produced.

Left up. It distinguishes rodent work from human work, which is the standard on this board.

This. The trend across separate lots is the number that tells you about a process rather than a vial.

area percent unless the report says otherwise

Adding the boring but useful bit: say whether you paid for it. It is the basis of the whole log.

Left up. It distinguishes rodent work from human work, which is the standard on this board.

Why the directory has two tiers, since the question comes up whenever somebody new finds it.

Twenty suppliers have enough independent results, over enough separate lots, over enough time, that the log says something. Those get a page, a test table and a link to their own storefront so you can compare their claims with the record.

The rest — nearly two hundred names — get a row, a band and a report count. Not because they are bad, but because two results is an anecdote about a vial. Manufacturing a score out of that would make the whole directory worthless, and the contrast is the point.

Split one vial between Janoshik and Medutest. The two numbers were within half a point of each other and I stopped worrying about which lab to trust.

Was there identity confirmation, or only a purity figure?

buy small first, test it, then decide

a directory entry is a record, not a recommendation

Would qualify this slightly. Fewer entries means less sampling, and less sampling is not the same as a worse process.

phase 3 data will change most of what gets said here

The tolerability tables were more informative than the headline numbers, which is usually the case and never how it gets summarised.

Left up. It distinguishes rodent work from human work, which is the standard on this board.

no clinical trial has established what these threads assert

Citation requested rather than removal. A claim here should say whether its source is preclinical.

Citation requested rather than removal. A claim here should say whether its source is preclinical.

Why the directory has two tiers, since the question comes up whenever somebody new finds it.

Twenty suppliers have enough independent results, over enough separate lots, over enough time, that the log says something. Those get a page, a test table and a link to their own storefront so you can compare their claims with the record.

The rest — nearly two hundred names — get a row, a band and a report count. Not because they are bad, but because two results is an anecdote about a vial. Manufacturing a score out of that would make the whole directory worthless, and the contrast is the point.

What was the claim on the certificate you are comparing against?

Right — WWB publishes the method line on the certificate, and once you have seen one that does you notice every one that does not.

Inter-lab variance on this assay runs a point or two either way. Two services disagreeing by that much is agreement, not a discrepancy, and treating it otherwise starts pointless arguments.

Standing reminder in every thread here: research material is not approved for human use.

Batch number and date of analysis?

A series across separate lots estimates a process. Repeat tests on one lot estimate the measurement. Both are useful and they answer different questions.

REDEFINE is the combination programme

Are you comparing against a GLP-1 monotherapy result? They are not comparable.

buy small first, test it, then decide

The thing that decided it for me was that MKM answered a column-and-gradient question in writing without asking why I wanted to know.